Additional file 2: of The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

Figure S1. A sequential exposure to palbociclib followed by PI3K/AKT/mTOR inhibitors alone induces additive effects. MDA-MB-231 were pre-incubated with 0.5 ÎźM palbociclib for 24h and then treated with increasing concentrations of BYL719 (a), BEZ235 (b) or BKM120 (c) alone. After 48h cell proliferation was assessed by CV assay. The effect of the drug combinations was evaluated using the Bliss interaction model. Data are mean values ÂąSD of three insdependent experiments (n = 5). (TIFF 437 kb)